KYMERA THERAPEUTICS, INC. Deferred Revenue, Revenue Recognized
KYMERA THERAPEUTICS, INC. (KYMR) reported Deferred Revenue, Revenue Recognized of $75.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. deferred revenue, revenue recognized for the quarter ending 2024-03-31 was $55.00M.
- KYMERA THERAPEUTICS, INC. deferred revenue, revenue recognized for fiscal 2025 was $75.00M, a 36.36% increase from fiscal 2024.
- KYMERA THERAPEUTICS, INC. deferred revenue, revenue recognized for fiscal 2024 was $55.00M.
| Period end | Deferred Revenue, Revenue Recognized 3 month | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 9 month | Deferred Revenue, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2025-12-31 | $75.00M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $75.00M 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $75.00M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $55.00M 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $55.00M 10-Q · filed 2024-10-31 | |||
| 2024-06-30 | $55.00M 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $55.00M 10-Q · filed 2024-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |